ARDX Material Contracts | ARDELYX, INC.

ARDELYX, INC. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-08-06: Form 10-Q; Exhibit 10.2; Description Second Amendment to the Manufacturing Services Agreement, dated May 15, 2026, by and between the Company and Patheon Pharmaceuticals Inc..
2026-08-06: Form 10-Q; Exhibit 10.1; Description First Amendment to the Commercial Supply Agreement, dated May 11, 2026, by and between the Company and Catalent Pharma Solutions, LLC..
2026-06-17: Form 8-K; Exhibit 10.1; Description Second Amendment to the Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan..
2026-04-30: Form 10-Q; Exhibit 10.3; Description Sixth Amendment to Loan and Security Agreement, dated April 28, 2026, by and among the Company, SLR Investment Corp., as collateral agent, and the lenders party thereto..

Filed	Form	Exhibit	Description
2026-08-06	10-Q	10.2	Second Amendment to the Manufacturing Services Agreement, dated May 15, 2026, by and between the Company and Patheon Pharmaceuticals Inc.
2026-08-06	10-Q	10.1	First Amendment to the Commercial Supply Agreement, dated May 11, 2026, by and between the Company and Catalent Pharma Solutions, LLC.
2026-06-17	8-K	10.1	Second Amendment to the Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan.
2026-04-30	10-Q	10.3	Sixth Amendment to Loan and Security Agreement, dated April 28, 2026, by and among the Company, SLR Investment Corp., as collateral agent, and the lenders party thereto.
2026-04-30	10-Q	10.2	Offer Letter, dated March 2, 2026, by and between Ardelyx, Inc. and Rajani Dinavahi, M.D.
2026-04-30	10-Q	10.1	Offer Letter, dated February 18, 2026, by and between Ardelyx, Inc. and Felecia Ettenberg.
2026-02-19	10-K	10.25	License Agreement, dated December 11, 2017, by and between Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. and Ardelyx, Inc.
2026-02-19	10-K	10.24.A	License Agreement, dated November 27, 2017, by and between Kyowa Hakko Kirin Co., Ltd. and Ardelyx, Inc.
2026-02-19	10-K	10.15	Fifth Amended and Restated Non-Employee Director Compensation Program.
2026-02-19	10-K	10.11	Transition and Separation Agreement, dated December 17, 2025, by and between Ardelyx, Inc. and Elizabeth Grammer.
2026-02-19	10-K	10.9	Transition and Separation Agreement, dated November 5, 2025, by and between Ardelyx, Inc. and David Rosenbaum.
2026-02-19	10-K	10.3.C	Form of Stock Option Grant Notice under the Amended and Restated 2014 Equity Incentive Award Plan.
2026-02-19	10-K	10.3.D	Form of Stock Option Agreement under the Amended and Restated 2014 Equity Incentive Award Plan.
2026-02-19	10-K	10.3.E	Form of Restricted Stock Unit Award Grant Notice under the Amended and Restated 2014 Equity Incentive Award Plan.
2026-02-19	10-K	10.3.F	Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2014 Equity Incentive Award Plan.
2026-02-19	10-K	10.3.G	Form of Non-Employee Director Stock Option Grant Notice under the Amended and Restated 2014 Equity Incentive Award Plan.
2026-02-19	10-K	10.3.H	Form of Non-Employee Director Stock Option Agreement under the Amended and Restated 2014 Equity Incentive Award Plan.
2026-02-19	10-K	10.3.I	Form of Non-Employee Director Restricted Stock Unit Award Grant Notice under the Amended and Restated 2014 Equity Incentive Award Plan.
2026-02-19	10-K	10.3.J	Form of Non-Employee Director Restricted Stock Unit Award Agreement under the Amended and Restated 2014 Equity Incentive Award Plan.
2025-10-30	10-Q	10.4	Offer Letter, dated May 29, 2025, by and between Ardelyx, Inc. and Edward Conner.
2025-10-30	10-Q	10.3	Offer Letter, dated June 29, 2025, by and between Ardelyx, Inc. and John Bishop.
2025-10-30	10-Q	10.2	Offer Letter, dated September 23, 2025, by and between Ardelyx, Inc. and Sue Hohenleitner.
2025-10-30	10-Q	10.1	Transition and Separation Agreement, dated August 1, 2025, by and between Ardelyx, Inc. and Justin Renz.
2025-08-04	10-Q	10.3	Offer Letter, dated April 10, 2025 by and between Ardelyx, Inc. and James P. Brady.
2025-08-04	10-Q	10.2	Amendment Number 4 to Lease Agreement by and between Ardelyx, Inc, and Prospect Fifth Avenue, LLC.
2025-07-03	8-K	10.1	Fifth Amendment to Loan and Security Agreement, dated June 30, 2025, by and among the Company, SLR Investment Corp., as collateral agent, and the lenders party thereto.
2025-06-18	8-K	10.1	First Amendment to the Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan.
2025-05-01	10-Q	10.3	Fourth Amended and Restated Non-Employee Director Compensation Program.
2025-05-01	10-Q	10.2	Form of Amended and Restated Change in Control and Severance Agreement for Executive Officers Other Than CEO.
2025-05-01	10-Q	10.1	Second Amended and Restated Executive Employment Agreement, dated April 29, 2025, by and between Ardelyx, Inc. and Michael Raab.
2024-10-31	10-Q	10.6	Offer Letter, dated July 25, 2024 by and between Alderyx, Inc. and Eric Foster.
2024-10-31	10-Q	10.5	Fourth Amendment to the Loan and Security Agreement dated October 29, 2024, by and between Ardelyx, Inc. and SLR Investment Corp.
2024-10-31	10-Q	10.2	Commercial Supply Agreement, dated October 25, 2024, by and among Ardelyx, Inc., Hovione Farmaciência, S.A. and Hovione, LLC.
2024-10-09	8-K	10.2	Sixth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc. and 34175 Ardenwood Venture, LLC
2024-10-09	8-K	10.1	Lease Agreement, dated October 3, 2024, by and between Ardelyx, Inc. and BMR-Pacific Research Center LP
2024-08-12	8-K	10.1	Commercial Supply Agreement, dated August 7, 2024 and effective as of July 23, 2024, by and between the Company and Catalent.
2024-08-01	10-Q	10.2	Ardelyx, Inc. Amended and Restated 2014 Employee Stock Purchase Plan.
2024-08-01	10-Q	10.1	Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan.
2024-06-17	8-K	10.2	Ardelyx, Inc. Amended and Restated 2014 Employee Stock Purchase Plan
2024-06-17	8-K	10.1	Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan
2024-05-02	10-Q	10.29	Offer Letter, dated February 13, 2024 by and between Ardelyx, Inc. and Michael Kelliher.
2024-05-02	10-Q	10.3.B	Amendment Number 2 to Lease Agreement by and between Ardelyx, Inc, and Prospect Fifth Avenue, LLC.
2024-05-02	10-Q	10.3.C	Amendment Number 3 to Lease Agreement by and between Ardelyx, Inc, and Prospect Fifth Avenue, LLC.
2024-02-22	10-K	10.20.B	Third Amended and Restated Non-Employee Director Compensation Program
2024-02-22	10-K	10.7.A	Ardelyx, Inc. 2016 Employment Commencement Incentive Plan
2023-10-18	8-K	10.1	Third Amendment to Loan and Security Agreement, dated October 17, 2023, by and among the Company, SLR Investment Corp., as collateral agent, and the lenders party thereto.
2023-03-02	10-K	10.27.B	First Amendment to the Manufacturing Services Agreement dated February 27, 2023, between Ardelyx, Inc. and Patheon Pharmaceuticals Inc.
2023-03-02	10-K	10.24.C	Second Amendment to the Loan and Security Agreement dated February 9, 2023, by and between Ardelyx, Inc. and SLR Investment Corp.
2023-03-02	10-K	10.21.B	Amendment Number 1 to License Agreement, dated as of November 27, 2017, by and among Ardelyx, Inc., and Kyowa Kirin Co., Ltd.
2023-03-02	10-K	10.2.E	Fourth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc. and 34175 Ardenwood Venture, LLC
2022-08-04	10-Q	10.3	Second Amended and Restated Non-Employee Director Compensation Program
2022-08-04	10-Q	10.2	First Amendment to the Loan and Security Agreement dated August 1, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.
2022-08-04	10-Q	10.1	Royalty and Sales Milestone Interest Acquisition Agreement dated June 29, 2022, by and between Ardelyx, Inc. and Healthcare Royalty Partners IV, L.P.
2022-05-05	10-Q	10.2	Exit Fee Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.
2022-05-05	10-Q	10.1	Loan and Security Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.
2022-02-28	10-K	10.22	Form of Executive Retention Agreement Version 2
2022-02-28	10-K	10.21	Form of Executive Retention Agreement Version 1
2022-02-28	10-K	10.20	Amendment Number One to Second Amended and Restated Change in Control Severance Agreement and Retention Agreement dated December 1, 2021 between Ardelyx, Inc. and David Rosenbaum
2022-02-28	10-K	10.19	Retention Agreement, dated October 25, 2021, by and between Ardelyx, Inc. and Justin Renz
2022-02-28	10-K	10.16	Retention Agreement, dated October 25, 2021, by and between Ardelyx, Inc. and Susan Rodriguez
2022-02-28	10-K	10.8	Retention Agreement, dated October 25, 2021, by and between Ardelyx, Inc. and Mike Raab
2021-08-17	8-K	10.1	Open Market Sales Agreement dated August 13, 2021, by and between Ardelyx, Inc. and Jefferies LLC.
2021-07-30	8-K	10.1	Fourth Amendment to the Loan and Security Agreement, dated as of July 29, 2021, by and among Ardelyx, Inc., Solar Capital Ltd. and the lenders party thereto.
2021-06-01	8-K	10.1	Fifth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc. and 34175 Ardenwood Venture, LLC
2021-05-06	10-Q	10.1	Third Amendment to the Loan and Security Agreement, dated May 5, 2021, by and between the Company and Solar Capital Ltd. and Western Alliance Bank.
2021-03-08	10-K	10.31	Lease Agreement, dated December 30, 2020, by and between Ardelyx, Inc. and Prospect Fifth Ave, LLC.
2020-10-14	8-K	10.1	First Amendment to Loan and Security Agreement, dated as of October 9, 2020, by and among Ardelyx, Inc., Solar Capital Ltd. and the lenders party
2020-08-06	10-Q	10.5	Manufacturing Services Agreement, dated May 18, 2020, between Ardelyx, Inc., and Patheon Pharmaceuticals Inc.
2020-08-06	10-Q	10.4	Change in Control Severance Agreement, dated June 8, 2020, by and between Ardelyx, Inc. and Justin Renz
2020-08-06	10-Q	10.3	Offer Letter, dated June 2, 2020, by and between Ardelyx, Inc. and Justin Renz
2020-08-06	10-Q	10.2	Change in Control Severance Agreement, dated June 2, 2020, by and between Ardelyx, Inc. and Susan Rodriquez
2020-08-06	10-Q	10.1	Offer Letter, dated April 27, 2020, by and between Ardelyx, Inc. and Susan Rodriguez
2020-03-06	10-K	10.30	Transition and Separation Agreement dated November 25, 2019, by and between the Company and Mark Kaufmann.
2019-05-07	10-Q	10.1	Amended and Restated Non-Employee Director Compensation Program.
2018-08-07	10-Q	10.3	Transition and Separation Agreement dated July 8, 2018, by and between the Company and Reginald Seeto, MBBS.
2018-08-07	10-Q	10.2	Exit Fee Agreement, dated May 16, 2018, by and between the Company and Solar Capital Ltd. and Western Alliance Bank.
2018-08-07	10-Q	10.1	Loan and Security Agreement, dated May 16, 2018, by and between the Company and Solar Capital Ltd. and Western Alliance Bank.
2018-05-08	10-Q	10.1	Second Amended and Restated Change in Control and Severance Agreement by and between Ardelyx, Inc. and David P. Rosenbaum, Ph.D.
2018-05-08	10-Q	10.0	Second Amended and Restated Change in Control and Severance Agreement by and between Ardelyx, Inc. and Elizabeth Grammer.
2018-03-14	10-K	10.36	License Agreement, dated December 11, 2017, by and between Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. and Ardelyx, Inc.
2018-03-14	10-K	10.35	License Agreement, dated November 27, 2017, by and between Kyowa Hakko Kirin Co., Ltd. and Ardelyx, Inc.
2017-11-07	10-Q	10.1	Transition and Separation Agreement dated August 21, 2017, by and between the Company and Dr. Paul Korner.
2017-02-17	10-K	10.33	Change in Control Severance Agreement, dated December 6, 2016, by and between Ardelyx, Inc. and Bryan Shaw.
2017-02-17	10-K	10.32	Offer Letter, dated November 15, 2016, by and between Ardelyx, Inc. and Bryan Shaw.
2017-02-17	10-K	10.31	Change in Control Severance Agreement, dated October 22, 2016, by and between Ardelyx, Inc. and Reginald Kim Seeto, MB.BS; B.Sc.
2017-02-17	10-K	10.30	Offer Letter, dated October 1, 2016, by and between Ardelyx, Inc. and Reginald Kim Seeto, MB.BS; B.Sc.
2017-02-17	10-K	10.29	Change in Control Severance Agreement, dated January 4, 2016, by and between Ardelyx, Inc. and Paul Korner, MD, MBA
2016-08-08	10-Q	10.3	Third Amendment to Lease by and between Ardelyx, Inc. and 34175 Ardenwood venture, LLC, dated as of April 28, 2016.
2016-08-08	10-Q	10.2	Registration Rights Agreement by and among Ardelyx, Inc. and the investors signatory thereto, dated July 14, 2016.
2016-08-08	10-Q	10.1	Securities Purchase Agreement by and among Ardelyx, Inc. and the purchasers signatory thereto, dated July 14, 2016.
2016-03-04	10-K	10.21	Offer Letter, dated December 12, 2015, by and between Ardelyx, Inc. and Paul Korner, MD, MBA
2016-03-04	10-K	10.1.D	Amendment No. 1 to Termination Agreement and to Manufacturing and Supply Agreement, dated November 2, 2015 by and between AstraZeneca AB and Ardelyx, Inc.
2015-08-12	10-Q	10.2	Securities Purchase Agreement by and among Ardelyx, Inc. and the purchasers signatory thereto, dated June 2, 2015.
2015-08-12	10-Q	10.1	Termination Agreement by and between Ardelyx, Inc. and AstraZeneca AZ, dated June 2, 2015.
2015-03-05	10-K	10.23	Change in Control Severance Agreement, dated December 19, 2014, by and between Ardelyx, Inc. and Jeremy S. Caldwell, Ph.D.
2015-03-05	10-K	10.22	Offer Letter, dated November 21, 2014, by and between Ardelyx, Inc. and Jeremy S. Caldwell, Ph.D.
2015-03-05	10-K	10.21	Change in Control Severance Agreement, dated November 26, 2014, by and Between Ardelyx, Inc. and Narani Arasaratnam.
2015-03-05	10-K	10.20	Offer Letter, dated October 15, 2014, by and between Ardelyx, Inc. and Narani Arasaratnam.
2014-09-09	8-K	10.2	Transition and Separation Agreement, dated September 4, 2014, by and between Ardelyx, Inc., and Dominique Charmot, Ph.D.
2014-09-09	8-K	10.1	Second Amendment to Lease, dated September 5, 2014, by and between Ardelyx, Inc., and Ardenwood Venture, LLC.

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Avalo Therapeutics, Inc. (AVTX)	United States	$0.842B	-9.74
Immix Biopharma, Inc. (IMMX)	United States	$0.837B	-18.44
Cryoport, Inc. (CYRX)	United States	$0.881B	-21.29
Theravance Biopharma, Inc. (TBPH)		$0.885B	16.40
Obsidian Therapeutics, Inc. (OBX)	United States	$0.829B
LEXICON PHARMACEUTICALS, INC. (LXRX)	United States	$0.823B	-17.48
RIGEL PHARMACEUTICALS INC (RIGL)	United States	$0.893B	2.25
GYRE THERAPEUTICS, INC. (GYRE)	United States	$0.818B	-24.71
Apnimed, Inc. (APMD)	United States	$0.899B
GERON CORP (GERN)	United States	$0.803B	-12.14